Home Tags Chemotherapy

Tag: chemotherapy

Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Study Shows Targeted ‘Click-to-release’ Chemotherapy Offers Positive Results in Mice

Antibody-drug Conjugates or ADCs are relatively new anti-cancer drugs.Consisting of an antibody linked to a cell-killing, chemotherapeutic agent, these agents are designed to target...

Antibody-drug conjugates: Recent Advances in Conjugation and Linker Chemistries

Authors: Tsuchikama K , An Z Title: Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Published in: Protein Cell. 2016 Oct 14.Keywords: antibody-drug conjugates; cancer;...

Study Shows High Remission Rate in Leukemia Patients Treated with Inotuzumab...

In an open-label, randomized Phase III INO-VATE ALL study, also known as study 1022, of the investigational drug inotuzumab ozogamicin, also known as CMC-544 (Pfizer), a...

Amgen Presents TOWER Study During 21st Congress of the European Hematology...

During the upcoming 21st Congress of the European Hematology Association (EHA), the premier hematology congress in Europe being held June 9-12, 2016, in Copenhagen, Denmark, Amgen...

Antigen Shedding and Targeted Delivery of Immunotoxins in Solid Tumors: A...

Cells modulate responses to signals in the extracellular environment by shedding cell surface antigens. Understanding this process is important because antibody-based anti-cancer therapies target...

EORTC Trial Starts for Elderly with HER-2 Positive Metastatic Breast Cancer

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate...

Updated Data for Brentuximab Vedotin Shows Durable Complete Remission and Manageable...

Updated data from a pivotal trial of single-agent brentuximab vedotin (adcetris™,Seattle Genetics) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)...

FDA Rejects Accelerated Approval For T-DM1, Global Regulatory Submission Expected In...

Earlier today the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the Roche's trastuzumab-DM1 (T-DM1) Biologics...

FEATURED RESOURCES